|
1
|
Prado CM, Lieffers JR, McCargar LJ, Reiman
T, Sawyer MB, Martin L and Baracos VE: Prevalence and clinical
implications of sarcopenic obesity in patients with solid tumours
of the respiratory and gastrointestinal tracts: A population-based
study. Lancet Oncol. 9:629–635. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peng P, Hyder O, Firoozmand A, Kneuertz P,
Schulick RD, Huang D, Makary M, Hirose K, Edil B, Choti MA, et al:
Impact of sarcopenia on outcomes following resection of pancreatic
adenocarcinoma. J Gastrointest Surg. 16:1478–1486. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harimoto N, Shirabe K, Yamashita YI,
Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y, Nishie A and
Yamanaka T: Sarcopenia as a predictor of prognosis in patients
following hepatectomy for hepatocellular carcinoma. Br J Surg.
100:1523–1530. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
van Vledder MG, Levolger S, Ayez N,
Verhoef C, Tran TC and Ijzermans JN: Body composition and outcome
in patients undergoing resection of colorectal liver metastases. Br
J Surg. 99:550–557. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lanic H, Kraut-Tauzia J, Modzelewski R,
Clatot F, Mareschal S, Picquenot JM, Stamatoullas A, Leprêtre S,
Tilly H and Jardin F: Sarcopenia is an independent prognostic
factor in elderly patients with diffuse large B-cell lymphoma
treated with immunochemotherapy. Leuk Lymphoma. 55:817–823. 2014.
View Article : Google Scholar
|
|
6
|
Tan BH, Birdsell LA, Martin L, Baracos VE
and Fearon KC: Sarcopenia in an overweight or obese patient is an
adverse prognostic factor in pancreatic cancer. Clin Cancer Res.
15:6973–6979. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goodpaster BH, Park SW, Harris TB,
Kritchevsky SB, Nevitt M, Schwartz AV, Simonsick EM, Tylavsky FA,
Visser M and Newman AB: The loss of skeletal muscle strength, mass,
and quality in older adults: The health, aging and body composition
study. J Gerontol A Biol Sci Med Sci. 61:1059–1064. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goodpaster BH, Kelley DE, Thaete FL, He J
and Ross R: Skeletal muscle attenuation determined by computed
tomography is associated with skeletal muscle lipid content. J Appl
Physiol (1985). 89:104–110. 2000.
|
|
9
|
Delmonico MJ, Harris TB, Visser M, Park
SW, Conroy MB, Velasquez-Mieyer P, Boudreau R, Manini TM, Nevitt M,
Newman AB, et al: Health, Aging, and Body: Longitudinal study of
muscle strength, quality, and adipose tissue infiltration. Am J
Clin Nutr. 90:1579–1585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Martin L, Birdsell L, Macdonald N, Reiman
T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB and
Baracos VE: Cancer cachexia in the age of obesity: Skeletal muscle
depletion is a powerful prognostic factor, independent of body mass
index. J Clin Oncol. 31:1539–1547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Antoun S, Lanoy E, Iacovelli R,
Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, Fizazi K, di Palma M,
Baracos VE and Escudier B: Skeletal muscle density predicts
prognosis in patients with metastatic renal cell carcinoma treated
with targeted therapies. Cancer. 119:3377–3384. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Prado CM, Baracos VE, McCargar LJ, Reiman
T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E and
Sawyer MB: Sarcopenia as a determinant of chemotherapy toxicity and
time to tumor progression in metastatic breast cancer patients
receiving capecitabine treatment. Clin Cancer Res. 15:2920–2926.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Antoun S, Baracos VE, Birdsell L, Escudier
B and Sawyer MB: Low body mass index and sarcopenia associated with
dose-limiting toxicity of sorafenib in patients with renal cell
carcinoma. Ann Oncol. 21:1594–1598. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mitsiopoulos N, Baumgartner RN, Heymsfield
SB, Lyons W, Gallagher D and Ross R: Cadaver validation of skeletal
muscle measurement by magnetic resonance imaging and computerized
tomography. J Appl Physiol (1985). 85:115–122. 1998.
|
|
16
|
Yamaoka Y, Fujitani K, Tsujinaka T,
Yamamoto K, Hirao M and Sekimoto M: Skeletal muscle loss after
total gastrectomy, exacerbated by adjuvant chemotherapy. Gastric
Cancer. 18:382–389. 2015. View Article : Google Scholar
|
|
17
|
Abdiev S, Kodera Y, Fujiwara M, Koike M,
Nakayama G, Ohashi N, Tanaka C, Sakamoto J and Nakao A: Nutritional
recovery after open and laparoscopic gastrectomies. Gastric Cancer.
14:144–149. 2011. View Article : Google Scholar : PubMed/NCBI
|
